Literature DB >> 12379612

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

D E Furst1, F C Breedveld, J R Kalden, J S Smolen, C E Antoni, J W J Bijlsma, G R Burmester, B Cronstein, E C Keystone, A Kavanaugh, L Klareskog.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12379612      PMCID： PMC1766714          DOI： 10.1136/ard.61.suppl_2.ii2

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  31 in total

Review 1.  Clinical guidelines: developing guidelines.

Authors:  P G Shekelle; S H Woolf; M Eccles; J Grimshaw
Journal:  BMJ       Date:  1999-02-27

2.  Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.

Authors:  L W Moreland; G Margolies; L W Heck; A Saway; C Blosch; R Hanna; W J Koopman
Journal:  J Rheumatol       Date:  1996-11       Impact factor: 4.666

3.  Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; H Bijl; J N Woody
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

Review 4.  Etanercept: a review of its use in rheumatoid arthritis.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

5.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

6.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Authors:  L W Moreland; M H Schiff; S W Baumgartner; E A Tindall; R M Fleischmann; K J Bulpitt; A L Weaver; E C Keystone; D E Furst; P J Mease; E M Ruderman; D A Horwitz; D G Arkfeld; L Garrison; D J Burge; C M Blosch; M L Lange; N D McDonnell; M E Weinblatt
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 7.  Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis.

Authors:  A F Kavanaugh
Journal:  Rheum Dis Clin North Am       Date:  1998-08       Impact factor: 2.670

8.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

Authors:  B Bresnihan; J M Alvaro-Gracia; M Cobby; M Doherty; Z Domljan; P Emery; G Nuki; K Pavelka; R Rau; B Rozman; I Watt; B Williams; R Aitchison; D McCabe; P Musikic
Journal:  Arthritis Rheum       Date:  1998-12

9.  Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; P Katsikis; F M Brennan; J Walker; H Bijl; J Ghrayeb
Journal:  Arthritis Rheum       Date:  1993-12

10.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

Authors:  R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann
Journal:  Arthritis Rheum       Date:  1998-09
View more
  17 in total

Review 1.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

Review 2.  Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis.

Authors:  M C Hochberg; J K Tracy; M Hawkins-Holt; R H Flores
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  Appropriate and effective management of rheumatoid arthritis.

Authors:  F C Breedveld; J R Kalden
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

Review 4.  [Modern antirheumatic pharmacotherapy. Low molecular weight substances vs. biologicals].

Authors:  J Sautner; B F Leeb
Journal:  Internist (Berl)       Date:  2005-12       Impact factor: 0.743

Review 5.  Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.

Authors:  Thomas Nothnagl; Burkhard F Leeb
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.

Authors:  Annamaria Iagnocco; Chiara Perella; Esperanza Naredo; Gary Meenagh; Fulvia Ceccarelli; Emanuela Tripodo; Stefania Basili; Guido Valesini
Journal:  Clin Rheumatol       Date:  2007-10-19       Impact factor: 2.980

7.  Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.

Authors:  P Sidiropoulos; G Bertsias; H D Kritikos; H Kouroumali; K Voudouris; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

Review 8.  [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies].

Authors:  Judith Sautner; Burkhard F Leeb
Journal:  Wien Med Wochenschr       Date:  2003

9.  Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients.

Authors:  Alexander Kokkinos; Alexios Iliopoulos; Paraskevi Greka; Anna Efthymiou; Nicholas Katsilambros; Petros P Sfikakis
Journal:  Clin Rheumatol       Date:  2003-11-15       Impact factor: 2.980

Review 10.  Safety of tumour necrosis factor-alpha antagonists.

Authors:  Dinesh Khanna; Maureen McMahon; Daniel E Furst
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.